This is a working overview of GHRH analogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-17 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
== Production == 60Co does not occur naturally on Earth in significant amounts, so 60Co is synthesized by bombarding a 59Co target with a thermal neutron source - in a commercial or industrial context, that means a nuclear reactor. The CANDU reactors can be used to activate 59Co, by substituting the control rods with cobalt rods. In the United States, as of 2010, it is being produced in a boiling water reactor at Hope Creek Nuclear Generating Station. The cobalt targets are substituted here for a small number of fuel assemblies. Still, over 40% of all single-use medical devices are sterilized using 60Co from Bruce nuclear generating station. The reaction in all cases is
== Mechanism of action == Dulaglutide binds to glucagon-like peptide 1 receptors, slowing gastric emptying and increasing insulin secretion by pancreatic Beta cells. Simultaneously the compound reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas, as glucagon is known to be inappropriately elevated in diabetic patients. GLP-1 is normally secreted by L cells of the gastrointestinal mucosa in response to a meal.
The major part of the PAP is the nèiwèi bùduì (Chinese: 内卫部队); translations include "internal security forces", "internal security troops", and "internal guards corps". Internal security forces are divided into provincial-level formations with geographical areas of responsibility. They are subordinated to PAP headquarters; the 2017-2018 reforms removed control of PAP units from local government. Internal security forces are focused on domestic security missions, maintaining stability in western China, guarding government compounds, disaster relief, and responding to major anti-government unrest. The zǒngduì (Chinese: 总队) is the provincial formation. They are called "corps" by the PAP; Western analysts have used "contingent", "general corps", and "detachment". Most are corps deputy leader grade formations. The exceptions are the Beijing and Xinjiang corps which are corps leader grade; their subordinate entities, except for the logistics and equipment bureaus, are one grade higher than in the other corps. Hong Kong and Macau do not have corps. Corps have mobile detachments and duty detachments (Chinese: 执勤支队; pinyin: zhíqín zhīduì). Duty detachments protect government compounds and perform routine duties; they may exist because the CCP lacks confidence in the ability of local public security forces to handle "mass incidents". Mobile detachments (Chinese: 机动支队; pinyin: jīdòng zhīduì) are rapid reaction units roughly corresponding to PLAGF regiments. Some were existing corps mobile units before the reforms. Most were transferred from the disbanded mobile divisions.
Despite the underlying notion of the lab as a confined space for experts, the term "laboratory" is also increasingly applied to workshop spaces such as Living Labs, Fab Labs, or Hackerspaces, in which people meet to work on societal problems or make prototypes, working collaboratively or sharing resources. This development is inspired by new, participatory approaches to science and innovation and relies on user-centred design methods and concepts like Open innovation or User innovation. One distinctive feature of work in Open Labs is the phenomenon of translation, driven by the different backgrounds and levels of expertise of the people involved.
Sources: en.wikipedia.org
=== US food distribution from 1900 to 1960 === The United States' food distribution system has experienced major changes in the past hundred years. Food distribution primarily relied on small, local farms in the 1940s, but quickly grew to become a large business in the 1960s. Three economic advances that allowed for the growth in food distribution between 1910 and 1960 were the establishment of chain stores, retail cooperatives, and supermarkets.
==== Train ==== Amtrak, the national passenger rail system, provides service to Albany from its Albany Station at 10th Avenue SW on two routes. Long-haul train route the Coast Starlight (with service from Los Angeles to Seattle) stops in Albany daily in both directions. Amtrak Cascades commuter trains operate between Vancouver, British Columbia and Eugene, Oregon, and serve Albany several times daily in each direction. The Amtrak Cascades line is the proposed path of the Pacific Northwest Corridor high-speed rail line. The Albany station would be one of many stops along the proposed 466-mile (750 km), 110-mile-per-hour (180 km/h) passenger line. The station itself was constructed in 1909 for the Southern Pacific Railroad and is built of masonry. It is one of the oldest continuously operating passenger rail stations in the U.S. and has one of the best-equipped engine shops in the northwest. Southern Pacific 4449, a steam locomotive which resides at the Oregon Rail Heritage Center in Portland, occasionally visited the shop for repairs when it was residing at the Brooklyn Roundhouse in Portland (before 2012), as did several other locomotives stored at the now-demolished roundhouse. Beginning in 2004, the station and the surrounding area underwent an $11.3 million restoration that was funded with a combination of federal, state, local, and Amtrak money. In 2006 the city received the Award in Downtown Excellence from the Oregon Downtown Development Association for the renovation of the station.
== In popular culture == The 1990 film Reversal of Fortune depicts the case and its surrounding fallout. For his portrayal of Claus von Bülow, Jeremy Irons won the Academy Award for Best Actor. Klaus and Sunny Baudelaire from A Series of Unfortunate Events are named after Claus and Sunny von Bülow.
Within any crystal, there will usually be some defects. To maintain electroneutrality of the crystals, defects that involve loss of a cation will be associated with loss of an anion, i.e. these defects come in pairs. Frenkel defects consist of a cation vacancy paired with a cation interstitial and can be generated anywhere in the bulk of the crystal, occurring most commonly in compounds with a low coordination number and cations that are much smaller than the anions. Schottky defects consist of one vacancy of each type, and are generated at the surfaces of a crystal, occurring most commonly in compounds with a high coordination number and when the anions and cations are of similar size. If the cations have multiple possible oxidation states, then it is possible for cation vacancies to compensate for electron deficiencies on cation sites with higher oxidation numbers, resulting in a non-stoichiometric compound. Another non-stoichiometric possibility is the formation of an F-center, a free electron occupying an anion vacancy. When the compound has three or more ionic components, even more defect types are possible. All of these point defects can be generated via thermal vibrations and have an equilibrium concentration. Because they are energetically costly but entropically beneficial, they occur in greater concentration at higher temperatures. Once generated, these pairs of defects can diffuse mostly independently of one another, by hopping between lattice sites.
=== Career === Baker joined the Department of Biochemistry at the University of Washington School of Medicine as a faculty member in 1993. He became a Howard Hughes Medical Institute investigator in 2000. Baker was elected a Fellow of the American Academy of Arts and Sciences in 2009.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.